A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too
August 24, 2022
-
REGULATORY MHLW to Boost Orphan Program to Fuel New Drug Development: FY2023 Budget Request
August 23, 2022
-
REGULATORY After Repeated Scandals, PMDA Sets Up New Division to Provide GMP Inspection Know-How to Prefectures
August 22, 2022
-
REGULATORY Operational Issues of Emergency Approval Scheme Will Be Addressed If Needed: Pharma Bureau Chief
August 19, 2022
-
BUSINESS Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
-
BUSINESS Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
-
ORGANIZATION JaDHA Hopes to Issue First Policy Proposal to Solve Digital Health Challenges by Year-End: Chairman
August 17, 2022
-
REGULATORY AZ’s Asthma Drug Tezepelumab Up for MHLW Panel Review on August 29
August 17, 2022
-
REGULATORY Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December
August 16, 2022
-
REGULATORY Authorized Generics Approved for Nexium, Samsca, Lipitor, Careram
August 16, 2022
-
REGULATORY First Generics for 5 APIs Approved towards December Listing, with 8 Firms for Nexium
August 16, 2022
-
REGULATORY Lilly’s GIP/GLP-1 Receptor Agonist Up for PAFSC Review on August 25
August 15, 2022
-
REGULATORY 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
-
BUSINESS Sumitomo Pharma to Rev Up R&D for Regenerative Medicine, CNS towards Later 2030s
August 12, 2022
-
REGULATORY Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
-
REGULATORY Rybelsus Faces 2.5-2.6% Price Cut in November under CEA Scheme; No Change for Cabometyx
August 10, 2022
-
BUSINESS Sumitomo Drops 100 Billion Yen Diabetes Sales Goal as Trulicity Collab Ends
August 10, 2022
-
BUSINESS Yen’s Fall Reaps 10 Billion Yen-Plus Gain on Sales for 5 Japan Makers, Takeda Gets 8.8 Billion Yen: April-June
August 9, 2022
-
BUSINESS Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
-
BUSINESS Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…